Moderna collaborates with Carisma to develop in vivo CAR-M therapeutics for oncology
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) and Carisma Therapeutics have entered into a strategic collaboration agreement to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for the treatment of cancer.
Under the terms of agreement, Carisma will receive a $45M up-front cash payment and an investment by Moderna in the form of a $35M convertible note.

Carisma will receive research funding and is eligible to receive milestone payments, plus royalties on net sales of any products that are commercialized under the agreement.
Carisma will be responsible for the discovery and optimization of development candidates while Moderna will lead the clinical development and commercialization of therapeutics resulting from the agreement.
Moderna has the option to nominate up to twelve targets for development and commercialization.